Axsome Therapeutics, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 32/100
What the filing says
On June 26, 2026, Axsome Therapeutics amended its loan agreement with Blackstone-led lenders to add $20,000,000 in incremental revolving credit commitments, increasing total revolving commitments from $70,000,000 to $90,000,000. The new commitments have identical terms to existing ones. Lenders include Axis Aggregator L.P., Blackstone Private Credit Fund, and Blackstone Secured Lending Fund. Axsome paid upfront fees matching prior revolving credit upfront fees.
Why this rating
Routine credit facility expansion (4.5% increase relative to $4.4B market cap, 0.45% of company size). Standard working capital financing with no strategic change to business operations or capital structure materially affecting trajectory.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.